Literature DB >> 31754958

Change in antibiotic regimen for emerging multidrug resistance in nosocomial ascitic fluid infection.

Seema Alam1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31754958      PMCID： PMC7223946          DOI： 10.1007/s12072-019-10000-5

Source DB:  PubMed          Journal:  Hepatol Int        ISSN： 1936-0533            Impact factor:   6.047


× No keyword cloud information.
  8 in total

1.  Management of adult patients with ascites due to cirrhosis: an update.

Authors:  Bruce A Runyon
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

2.  Ascitic fluid infection in children with liver disease: time to change empirical antibiotic policy.

Authors:  Sumit Kumar Singh; Ujjal Poddar; Richa Mishra; Anshu Srivastava; Surender Kumar Yachha
Journal:  Hepatol Int       Date:  2019-07-09       Impact factor: 6.047

3.  Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae.

Authors:  Jiachun Su; Qinglan Guo; Ying Li; Shi Wu; Fupin Hu; Su Xu; Minggui Wang
Journal:  J Antimicrob Chemother       Date:  2018-11-01       Impact factor: 5.790

4.  Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide.

Authors:  Salvatore Piano; Virendra Singh; Paolo Caraceni; Rakhi Maiwall; Carlo Alessandria; Javier Fernandez; Elza Cotrim Soares; Dong Joon Kim; Sung Eun Kim; Monica Marino; Julio Vorobioff; Rita de Cassia Ribeiro Barea; Manuela Merli; Laure Elkrief; Victor Vargas; Aleksander Krag; Shivaram Prasad Singh; Laurentius Adrianto Lesmana; Claudio Toledo; Sebastian Marciano; Xavier Verhelst; Florence Wong; Nicolas Intagliata; Liane Rabinowich; Luis Colombato; Sang Gyune Kim; Alexander Gerbes; Francois Durand; Juan Pablo Roblero; Kalyan Ram Bhamidimarri; Thomas D Boyer; Marina Maevskaya; Eduardo Fassio; Hyoung Su Kim; Jae Seok Hwang; Pere Gines; Adrian Gadano; Shiv Kumar Sarin; Paolo Angeli
Journal:  Gastroenterology       Date:  2018-12-13       Impact factor: 22.682

5.  Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study.

Authors:  Javier Fernández; Juan Acevedo; Miriam Castro; Orlando Garcia; Carlos Rodríguez de Lope; Daria Roca; Marco Pavesi; Elsa Sola; Leticia Moreira; Anibal Silva; Tiago Seva-Pereira; Francesco Corradi; Jose Mensa; Pere Ginès; Vicente Arroyo
Journal:  Hepatology       Date:  2012-04-04       Impact factor: 17.425

6.  The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial.

Authors:  Salvatore Piano; Silvano Fasolato; Freddy Salinas; Antonietta Romano; Marta Tonon; Filippo Morando; Marta Cavallin; Elisabetta Gola; Antonietta Sticca; Arianna Loregian; Giorgio Palù; Giacomo Zanus; Marco Senzolo; Patrizia Burra; Umberto Cillo; Paolo Angeli
Journal:  Hepatology       Date:  2015-08-04       Impact factor: 17.425

7.  Extensively drug-resistant bacteria are an independent predictive factor of mortality in 130 patients with spontaneous bacterial peritonitis or spontaneous bacteremia.

Authors:  Alexandra Alexopoulou; Larisa Vasilieva; Danai Agiasotelli; Kyriaki Siranidi; Sophia Pouriki; Athanasia Tsiriga; Marina Toutouza; Spyridon P Dourakis
Journal:  World J Gastroenterol       Date:  2016-04-21       Impact factor: 5.742

8.  Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.

Authors:  Patrick N A Harris; Paul A Tambyah; David C Lye; Yin Mo; Tau H Lee; Mesut Yilmaz; Thamer H Alenazi; Yaseen Arabi; Marco Falcone; Matteo Bassetti; Elda Righi; Benjamin A Rogers; Souha Kanj; Hasan Bhally; Jon Iredell; Marc Mendelson; Tom H Boyles; David Looke; Spiros Miyakis; Genevieve Walls; Mohammed Al Khamis; Ahmed Zikri; Amy Crowe; Paul Ingram; Nick Daneman; Paul Griffin; Eugene Athan; Penelope Lorenc; Peter Baker; Leah Roberts; Scott A Beatson; Anton Y Peleg; Tiffany Harris-Brown; David L Paterson
Journal:  JAMA       Date:  2018-09-11       Impact factor: 56.272
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.